Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supaglutide in Chinese Patients With Type 2 Diabetes Mellitus
CTR20191778Phase 2Completed
- Sponsor
- Yinno Pharma
- Start
- Mar 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of efsubaglutide alfa in type 2 diabetes mellitus (T2DM), sponsored by Yinno Pharma. Started Mar 2020; status: completed.
02
Drugs
efsubaglutide alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20191778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191778.